Service With A Smile was among 10 programs from nine universities to receive funding this year through the ADA Foundation’s E. “Bud” Tarrson Dental School Student Community Leadership Awards.

David Willens
Apr 1, 2011; 29:60-68
Feature Articles

London : Bailliere, Tindall and Cox, 1885.

Madras : printed by C. Foster, 1876.

Paper by Mr Luiz Awazu Pereira da Silva, Deputy General Manager of the BIS, Enisse Kharroubi, Emanuel Kohlscheen and Benoît Mojon based on remarks at the University of Basel, 5 May 2019.

Everyone knows SOLIDWORKS is very flexible and user friendly to execute the commands to complete any 3D design easily. When it comes to handling Complex assemblies (Increased in number of components) many of us will search for special tools to

Author information

The post SOLIDWORKS Quick tips – Advanced Component Selection appeared first on SOLIDWORKS Tech Blog.

By automatically enrolling all students in high-level courses, schools in Washington state are working to erase a long entrenched form of inequity.

The American Academy of Pediatrics recommends that all preterm infants receive human milk; however, little is known about the use of human milk in US advanced care neonatal units.

Routine use of human milk and use of donor milk in neonatal advanced care units increased from 2007 to 2011, particularly among units providing intensive care. There is geographic variation in the use of human milk in these units. (Read the full article)

Although physicians worry that communicating about prognosis or life-threatening illness can take away hope, previous work suggests that prognosis communication may even enhance hope. The nature of hopes held by parents of children with advanced cancer was not previously understood.

Parents in our study frequently recognized their child’s poor prognosis, yet held many different hopes, including for cure, quality of life, and meaningful relationships. Parents who hoped for cure often recognized that this was not possible for their child. (Read the full article)

One of the reasons for the lengthy tuberculosis (TB) treatment is the difficult to treat non-multiplying mycobacterial subpopulation. In order to assess the ability of (new) TB drugs to target this subpopulation, we need to incorporate dormancy models in our pre-clinical drug development pipeline. In most available dormancy models it takes a long time to create a dormant state and it is difficult to identify and quantify this non-multiplying condition.

The Mycobacterium tuberculosis 18b strain might overcome some of these problems, because it is dependent on streptomycin for growth and becomes non-multiplying after 10 days of streptomycin starvation, but still can be cultured on streptomycin-supplemented culture plates. We developed our 18b dormancy time-kill kinetic model to assess the difference in the activity of isoniazid, rifampicin, moxifloxacin and bedaquiline against log-phase growth compared to the non-multiplying M. tuberculosis subpopulation by CFU counting including a novel AUC-based approach as well as time-to-positivity (TTP) measurements.

We observed that isoniazid and moxifloxacin were relatively more potent against replicating bacteria, while rifampicin and high dose bedaquiline were equally effective against both subpopulations. Moreover, the TTP data suggest that including a liquid culture-based method could be of additional value as it identifies a specific mycobacterial subpopulation that is non-culturable on solid media.

In conclusion, the results of our study underline that the time-kill kinetics 18b dormancy model in its current form is a useful tool to assess TB drug potency and thus has its place in the TB drug development pipeline.

Google has made it easier to join the company's Advanced Protection Program, which is designed to stop the most sophisticated hackers from breaking into your Gmail account. Before you needed two security keys to enroll. Now you just need a smartphone.

AP has managed to dodge the partisan pitfalls that have felled other ambitious curricular efforts—so far, write Chester E. Finn Jr. and Andrew E. Scanlan.

For beginners, how marketers can learn to create advanced data models from time series data

Road mishaps cost India 3-5% of its gross domestic product every year. India amounts to one percent of the vehicles across the world, yet it contributes almost 6% of the road fatalities on the road.

Datsun’s Go as well as Go+ models have now received a CVT option. These come in the top trim and boast a slightly higher fuel efficiency compared to their manual counterparts or at par. How are they to drive? Take a look at our video.

Test chips are becoming more widespread and more complex at advanced process nodes as design teams utilize early silicon to diagnose problems prior to production. But this approach also is spurring questions about whether this approach is viable at 7nm and 5nm, due to the rising cost of prototyping advanced technology, such as mask tooling and wafer costs.

Semiconductor designers have long been making test chips to validate test structures, memory bit cells, larger memory blocks, and precision analog circuits like current mirrors, PLLs, temperature sensors, and high-speed I/Os. This has been done at 90nm, 65nm, 40nm, 32nm, 28nm, etc., so having test chips at 16nm, 7nm, or finer geometries should not be a surprise. Still, as costs rise, there is debate about whether those chips are over-used given advancements in tooling, or whether they should be utilized even more, with more advanced diagnostics built into them.

Modern EDA tools are very good. You can simulate and validate almost anything with certain degree of accuracy and correctness. The key to having good and accurate tools and accurate results (for simulation) is the quality of the foundry data provided. The key to having good designs (layouts) is that the DRC deck must be of high quality and accurate and must catch all the things you are not supposed to do in the layout. Most of the challenges in advanced node is in the FEOL where semiconductor physics and lithography play outsize roles. Issues that were not an issue at more mature nodes can manifest themselves as big problems at 7nm or 5nm. Process variation across the wafer and variation across a large die also present problems that were of no consequence in more mature nodes.

The real questions to be asked are as follows:

What is the role of test chips in SoC designs?

1. Do all hard IP require test chips for validation?
2. Are test chips more important at advanced nodes compared to more mature nodes?
3. Is the importance of test chip validation relative to the type of IP protocols?
4. What are the risks if I do not validate in silicon?

In complex SoC designs, there are many high-performance protocols such as LPDDR4/4x PHY, PCIe4 PHY, USB3.0 PHY, 56G/112G SerDes, etc. Each one of these IP are very complex in and by itself. If there is any chance of failure that is not detected prior to SoC (tapeout) integration, the cost of retrofit is huge. This is why the common practice is to validate each one of these complex IP in silicon before committing to use such IP in chip integration. The test chips are used to validate that the IP are properly designed and meet the functional specifications of the protocols. They are also used to validate if sufficient margins are designed into the IP to mitigate variances due to process tolerances. All high-performance hard IP go through this test chip/silicon validation process. Oftentimes, marginality is detected at this stage. In advanced nodes, it is also important to have the test chips built under different process corners. This is intended to simulate process variations in production wafers so as to maximize yields. Advanced protocols such as 112G, GDDR6, HBM2, and PCIe4 are incredibly complex and sensitive to process variations. It is almost impossible to design these circuits and try to guarantee their performance without going through the test chip route.

Besides validating performance of the IP protocols, test silicon is also used to validate robustness of ESD structures, sensitivity to latch up, and performance degradation over wide temperature ranges. All these items are more critical in advanced nodes than more mature modes. Test chips are vehicles to guarantee design integrity in bite-size chunks. It is better to deal with any potential issues in smaller blocks than to try to fix them in the final integrated SoC.

Test chips will continue to play a vital role in helping IP and SoC teams lower the risk of their designs, and assuring optimal quality and performance in the foreseeable future. They are not going away!

To read more, please visit https://semiengineering.com/test-chips-play-larger-role-at-advanced-nodes/

We have talked about aspects of the in-design symbol edit application mode in the past. This is the environment specific to the Allegro® Package Designer Plus layout tools allowing you to work...

[[ Click on the title to access the full blog on the Cadence Community site. ]]

We have talked about aspects of the in-design symbol edit application mode in the past. This is the environment specific to the Allegro Package Designer layout tools allowing you to work on symbol definitions directly in the context of your layout de...(read more)

WordPress WooCommerce Advanced Order Export plugin version 3.1.3 suffers from a cross site scripting vulnerability.

Online Shopping System Advanced version 1.0 suffers from a remote SQL injection vulnerability.

Hashcat is an advanced GPU hash cracking utility that includes the World's fastest md5crypt, phpass, mscash2 and WPA / WPA2 cracker. It also has the first and only GPGPU-based rule engine, focuses on highly iterated modern hashes, single dictionary-based attacks, and more. This is the binary release..

Hashcat is an advanced GPU hash cracking utility that includes the World's fastest md5crypt, phpass, mscash2 and WPA / WPA2 cracker. It also has the first and only GPGPU-based rule engine, focuses on highly iterated modern hashes, single dictionary-based attacks, and more. This is the source code release.

Hashcat is an advanced GPU hash cracking utility that includes the World's fastest md5crypt, phpass, mscash2 and WPA / WPA2 cracker. It also has the first and only GPGPU-based rule engine, focuses on highly iterated modern hashes, single dictionary-based attacks, and more. This is the binary release.

Hashcat is an advanced GPU hash cracking utility that includes the World's fastest md5crypt, phpass, mscash2 and WPA / WPA2 cracker. It also has the first and only GPGPU-based rule engine, focuses on highly iterated modern hashes, single dictionary-based attacks, and more. This is the source code release.

Hashcat is an advanced GPU hash cracking utility that includes the World's fastest md5crypt, phpass, mscash2 and WPA / WPA2 cracker. It also has the first and only GPGPU-based rule engine, focuses on highly iterated modern hashes, single dictionary-based attacks, and more. This is the binary release.

Hashcat is an advanced GPU hash cracking utility that includes the World's fastest md5crypt, phpass, mscash2 and WPA / WPA2 cracker. It also has the first and only GPGPU-based rule engine, focuses on highly iterated modern hashes, single dictionary-based attacks, and more. This is the source code release.

Hashcat is an advanced GPU hash cracking utility that includes the World's fastest md5crypt, phpass, mscash2 and WPA / WPA2 cracker. It also has the first and only GPGPU-based rule engine, focuses on highly iterated modern hashes, single dictionary-based attacks, and more. This is the binary release.

Hashcat is an advanced GPU hash cracking utility that includes the World's fastest md5crypt, phpass, mscash2 and WPA / WPA2 cracker. It also has the first and only GPGPU-based rule engine, focuses on highly iterated modern hashes, single dictionary-based attacks, and more. This is the source code release.

Hashcat is an advanced GPU hash cracking utility that includes the World's fastest md5crypt, phpass, mscash2 and WPA / WPA2 cracker. It also has the first and only GPGPU-based rule engine, focuses on highly iterated modern hashes, single dictionary-based attacks, and more. This is the binary release.

Hashcat is an advanced GPU hash cracking utility that includes the World's fastest md5crypt, phpass, mscash2 and WPA / WPA2 cracker. It also has the first and only GPGPU-based rule engine, focuses on highly iterated modern hashes, single dictionary-based attacks, and more. This is the source code release.

Hashcat is an advanced GPU hash cracking utility that includes the World's fastest md5crypt, phpass, mscash2 and WPA / WPA2 cracker. It also has the first and only GPGPU-based rule engine, focuses on highly iterated modern hashes, single dictionary-based attacks, and more. This is the binary release.

Hashcat is an advanced GPU hash cracking utility that includes the World's fastest md5crypt, phpass, mscash2 and WPA / WPA2 cracker. It also has the first and only GPGPU-based rule engine, focuses on highly iterated modern hashes, single dictionary-based attacks, and more. This is the source code release.

Hashcat is an advanced GPU hash cracking utility that includes the World's fastest md5crypt, phpass, mscash2 and WPA / WPA2 cracker. It also has the first and only GPGPU-based rule engine, focuses on highly iterated modern hashes, single dictionary-based attacks, and more. This is the binary release.

Hashcat is an advanced GPU hash cracking utility that includes the World's fastest md5crypt, phpass, mscash2 and WPA / WPA2 cracker. It also has the first and only GPGPU-based rule engine, focuses on highly iterated modern hashes, single dictionary-based attacks, and more. This is the source code release.

An upcoming virtual conference to share Australian insights in engineering research and technology innovation, and avenue to exchange research ideas with Malaysian researchers.

ADB has approved a $100 million loan to help supply renewable energy to Mongolia by installing its first large-scale advanced battery energy storage system.

Title: Provenge Approved for Advanced Prostate Cancer
Category: Health News
Created: 4/29/2010 2:10:00 PM
Last Editorial Review: 4/30/2010 12:00:00 AM

Title: Drugs Show Promise for Some Advanced Lung Cancers
Category: Health News
Created: 4/29/2015 12:00:00 AM
Last Editorial Review: 4/30/2015 12:00:00 AM

This first-in-human phase I study evaluated the pharmacokinetics, safety, and preliminary efficacy of telisotuzumab, formerly called ABT-700, an antagonistic antibody directed against c-Met. For dose escalation (3+3 design), 3 to 6 patients with advanced solid tumors were enrolled into four dose cohorts (5–25 mg/kg). In the dose-expansion phase, a subset of patients was prospectively selected for MET amplification (FISH screening). Patients received telisotuzumab intravenously on day 1 every 21 days. For dose expansion, 15 mg/kg was chosen as the dose on the basis of safety, pharmacokinetics, and other data from the escalation cohorts. Forty-five patients were enrolled and received at least one dose of telisotuzumab (dose escalation, n = 15; dose expansion, n = 30). Telisotuzumab showed a linear pharmacokinetics profile; peak plasma concentration was proportional to dose level. There were no acute infusion reactions and no dose-limiting toxicities were observed. The most common treatment-related adverse events included hypoalbuminemia (n = 9, 20.0%) and fatigue (n = 5, 11.1%). By Response Evaluation Criteria In Solid Tumors (RECIST), 4 of 10 (40.0%) patients with MET-amplified tumors had confirmed partial response in target lesions (one ovarian, two gastric, and one esophageal), two (20.0%) had stable disease, three (30.0%) had progressive disease; one patient was unable to be evaluated. Among patients with nonamplified tumors (n = 35), no objective responses were observed; however, 11 patients had stable disease per RECIST criteria. In conclusion, telisotuzumab has an acceptable safety profile with clinical activity observed in patients with MET-amplified advanced solid tumors.

Expression of the DNA/RNA helicase schlafen family member 11 (SLFN11) has been identified as a sensitizer of tumor cells to DNA-damaging agents including platinum chemotherapy. We assessed the impact of SLFN11 expression on response to platinum chemotherapy and outcomes in patients with metastatic castration-resistant prostate cancer (CRPC). Tumor expression of SLFN11 was assessed in 41 patients with CRPC treated with platinum chemotherapy by RNA sequencing (RNA-seq) of metastatic biopsy tissue (n = 27) and/or immunofluorescence in circulating tumor cells (CTC; n = 20). Cox regression and Kaplan–Meier methods were used to evaluate the association of SLFN11 expression with radiographic progression-free survival (rPFS) and overall survival (OS). Multivariate analysis included tumor histology (i.e., adenocarcinoma or neuroendocrine) and the presence or absence of DNA repair aberrations. Patient-derived organoids with SLFN11 expression and after knockout by CRISPR-Cas9 were treated with platinum and assessed for changes in dose response. Patients were treated with platinum combination (N = 38) or platinum monotherapy (N = 3). Median lines of prior therapy for CRPC was two. Median OS was 8.7 months. Overexpression of SLFN11 in metastatic tumors by RNA-seq was associated with longer rPFS compared with those without overexpression (6.9 vs. 2.8 months, HR = 3.72; 95% confidence interval (CI), 1.56–8.87; P < 0.001); similar results were observed for patients with SLFN11-positive versus SLFN11-negative CTCs (rPFS 6.0 vs. 2.2 months, HR = 4.02; 95% CI, 0.77–20.86; P = 0.002). A prostate-specific antigen (PSA) decline of ≥50% was observed in all patients with SLFN11 overexpression. No association was observed between SLFN11 expression and OS. On multivariable analysis, SLFN11 was an independent factor associated with rPFS on platinum therapy. Platinum response of organoids expressing SLFN11 was reduced after SLFN11 knockout. Our data suggest that SLFN11 expression might identify patients with CRPC with a better response to platinum chemotherapy independent of histology or other genomic alterations. Additional studies, also in the context of PARP inhibitors, are warranted.

Negative circumferential resection margins (CRM) are the cornerstone for the curative treatment of locally advanced rectal cancer (LARC). However, in up to 18.6% of patients, tumor-positive resection margins are detected on histopathology. In this proof-of-concept study, we investigated the feasibility of optical molecular imaging as a tool for evaluating the CRM directly after surgical resection to improve tumor-negative CRM rates. Methods: LARC patients treated with neoadjuvant chemoradiotherapy received an intravenous bolus injection of 4.5 mg of bevacizumab-800CW, a fluorescent tracer targeting vascular endothelial growth factor A, 2–3 d before surgery (ClinicalTrials.gov identifier: NCT01972373). First, for evaluation of the CRM status, back-table fluorescence-guided imaging (FGI) of the fresh surgical resection specimens (n = 8) was performed. These results were correlated with histopathology results. Second, for determination of the sensitivity and specificity of bevacizumab-800CW for tumor detection, a mean fluorescence intensity cutoff value was determined from the formalin-fixed tissue slices (n = 42; 17 patients). Local bevacizumab-800CW accumulation was evaluated by fluorescence microscopy. Results: Back-table FGI correctly identified a tumor-positive CRM by high fluorescence intensities in 1 of 2 patients (50%) with a tumor-positive CRM. For the other patient, low fluorescence intensities were shown, although (sub)millimeter tumor deposits were present less than 1 mm from the CRM. FGI correctly identified 5 of 6 tumor-negative CRM (83%). The 1 patient with false-positive findings had a marginal negative CRM of only 1.4 mm. Receiver operating characteristic curve analysis of the fluorescence intensities of formalin-fixed tissue slices yielded an optimal mean fluorescence intensity cutoff value for tumor detection of 5,775 (sensitivity of 96.19% and specificity of 80.39%). Bevacizumab-800CW enabled a clear differentiation between tumor and normal tissue up to a microscopic level, with a tumor-to-background ratio of 4.7 ± 2.5 (mean ± SD). Conclusion: In this proof-of-concept study, we showed the potential of back-table FGI for evaluating the CRM status in LARC patients. Optimization of this technique with adaptation of standard operating procedures could change perioperative decision making with regard to extending resections or applying intraoperative radiation therapy in the case of positive CRM.